Everyone is at risk for glaucoma. Early diagnosis is the first step in preserving your patients' vision.
According to the World Health Organization, it is estimated that 4.5 million people globally are blind due to glaucoma. It is estimated that this number will rise to 11.2 million people by 2020. That’s a 149% increase—6.7 million more people who may be at risk of losing their vision to this "silent blinding disease", and they have no idea it's even happening. We can help them. Together, let's provide educational resources about glaucoma, its causes and risk factors, and share simple steps that can be taken to proactively preserve one's vision.
Glaucoma is a group of eye diseases that damages the optic nerve. Optic nerve damage is caused by increased pressure from fluid that builds up inside the eye. Glaucoma affects peripheral (or side) vision, narrowing the field of view. Left untreated, glaucoma can cause total vision loss. Glaucoma can affect one or both eyes.
Watch the video to learn how ultra-widefield imaging with ZEISS CLARUS 500 can help detect diseases that might otherwise go undetected.
Take a proactive approach to preventing vision damage caused by glaucoma by scheduling regular vision screenings. That is every two to four years for patients under 40-years-old and more frequently with age. High risk patients should be tested every year or two after age 35. And, after age 65, eye exams should be scheduled every six months to a year.
A comprehensive screening for glaucoma includes checking for five factors before making a diagnosis:
Share these easy-to-understand guides with your patients and help them understand the importance of proactive retinal health checks powered by advanced imaging technologies at your practice.
Recent studies have revealed that in early stage glaucoma, macular damage may occur. Detecting central glaucoma early allows you to start monitoring your patient earlier for improved care and on regular visits for visual field testing. With the new 24-2C central test—which adds ten additional test points and represents the location of the nerve bundles in the macula region—you can optimize your glaucoma management. Learn more by watching this video featuring glaucoma specialist, Dr. Gustavo De Moraes of Columbia University.
Read an interesting study authored by Dr. Anders Heijl, Dr. Vincent Michael Patella, and others, on the validity of the Swedish Interactive Thresholding Algorithm (SITA) Faster compared to SITA Fast and SITA Standard.
Glaucoma is a complex progressive disease that requires continuous follow-up assessment. The gold standard in glaucoma care has been visual field testing, while optical coherence tomography has shown to play a significant role in enabling clinicians to identify changes in progression that could impact disease management. When data from the two exams are combined and associated, the results can be eye-opening.
As a clinician, your patient is your first priority, and that means providing the best level of care available today. However, that's not all that is needed. The burgeoning patient population also demands efficiency from doctors and practices, and while the advent of new and better technologies have elevated care for patients, clinicians no longer have the time to log onto multiple platforms to review different sets of data.
Enter the Integrated Diagnostic Imaging platform from ZEISS, the software-driven multi-modality solution that gathers, combines and associates data from different diagnostic devices, improving decision-making and efficiency.
http://www.health.gov.tt/news/newsitem.aspx?id=334; referencing the World Health Organization (WHO)
Glaucoma Research Foundation, Glaucoma Facts & Stats; https://www.glaucoma.org/glaucoma/glaucoma-facts-and-stats.php
Glaucoma Research Foundation, Are you at risk for glaucoma?; https://www.glaucoma.org/glaucoma/are-you-at-risk-for-glaucoma.php
National Eye Health Education Program (NEHEP), Learn About Glaucoma; https://nei.nih.gov/nehep/programs/glaucoma/learn-about